peptigrade.io$ subscribe

Metabolic & Weight

Tirzepatide

Dual GIP / GLP-1 receptor agonist·Also known as: Mounjaro, Zepbound

FDARegulatory status

Approved (2022 diabetes, 2023 obesity)

WADARegulatory status

Permitted in athletic competition

Regulatory note ·Marketed by Eli Lilly as Mounjaro (T2D) and Zepbound (obesity). The first dual incretin agonist approved by the FDA. Phase 3 SURMOUNT program established the largest non-surgical weight loss effect on record.

§ The quick take

TL;DR · Editor’s summary

Tirzepatide is the current best-in-class metabolic peptide. The dual mechanism (activating both GIP and GLP-1 receptors) produces greater weight loss and glycemic control than single-receptor agonists like semaglutide.

The Phase 3 program is one of the largest in modern endocrinology. Side effect profile is similar to semaglutide — predominantly GI, dose-dependent.

The honest read: this is an A-grade drug for obesity and T2D, with rapidly accumulating B-grade evidence in adjacent indications.

§ Grade matrix

The grade
per outcome.

One peptide can earn very different grades for different uses. Here is every outcome we’ve graded for Tirzepatide, sorted by strength of evidence.

Grade
Outcome
One-line take
Studies
Updated
A

Obesity (BMI ≥30)

Strong

SURMOUNT-1 produced 20.9% mean body weight reduction at 15 mg over 72 weeks. Roughly 5 percentage points beyond semaglutide.

56
Apr 02, 2026
A

Type 2 diabetes

Strong

SURPASS program (5 trials) showed HbA1c reductions of 1.9–2.3% — superior to comparator GLP-1 agonists.

92
Mar 26, 2026
B

Obstructive sleep apnea

Promising

SURMOUNT-OSA showed mean AHI reduction of 25–29 events/hour in obese patients with moderate-to-severe OSA.

8
Feb 12, 2026
B

Heart failure (HFpEF + obesity)

Promising

SUMMIT trial showed reduced HF events and improved KCCQ scores in obese HFpEF patients.

6
Mar 04, 2026
B

MASH / NASH

Promising

SYNERGY-NASH showed histologic resolution in 51.8% of treated vs 9.8% placebo at 52 weeks.

11
Feb 24, 2026

§ Why this grade

Sub-scores for this outcome.

Obesity

Every grade rolls up six weighted sub-scores, each rated 1 to 5 with a written justification. Here is how the top-outcome grade was constructed.

Mechanism understood

4 / 5

Dual GIP/GLP-1 activation characterized. GIP contribution still being teased apart.

Human studies (count + quality)

5 / 5

Phase 3 SURMOUNT program with 5,000+ patients. Active comparator trials.

Effect vs placebo

5 / 5

20.9% placebo-adjusted weight loss is the largest non-surgical effect on record.

Long-term safety data

3 / 5

3+ years of post-marketing data. Known GI profile. Long-term CV outcomes pending.

Side effect profile

3 / 5

GI predominant, similar to semaglutide. Discontinuation 6–7% in trials.

Regulatory status

5 / 5

FDA-approved for two indications. EMA-approved. OSA approval added 2024.

§ What the science says

How Tirzepatide
works.

Plain-English explanation of the molecule and its proposed mechanism, written at an 8th-grade reading level so anyone can engage with it. Every claim is linked to a primary source below.

What it is

Tirzepatide is a 39-amino-acid synthetic peptide engineered by Eli Lilly to activate two incretin receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1. It was approved by the FDA in 2022 for type 2 diabetes (Mounjaro) and in 2023 for chronic weight management (Zepbound). Within two years of launch it became one of the fastest-growing drugs in pharmaceutical history.

How it works

  1. 01

    Tirzepatide is a single peptide engineered to activate both the GIP and GLP-1 receptors. The dual activation appears to produce additive — and in some endpoints synergistic — metabolic effects.

  2. 02

    GLP-1 activation provides the same benefits as semaglutide: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and central appetite reduction.

  3. 03

    GIP activation enhances insulin secretion in a complementary way and may improve adipocyte function and lipid handling — the GIP arm is hypothesized to drive the additional weight-loss effect over GLP-1 alone.

  4. 04

    Like semaglutide, the central effect on appetite circuits in the hypothalamus is a major contributor to the body weight reduction observed in trials.

§ Investigated uses

What it’s
been studied for.

Investigated does not mean proven. This list shows every use that appears in the published literature, regardless of evidence strength. See the grade matrix above for which ones have actually held up.

  • Chronic weight management (obesity)

    FDA-approved (Zepbound) — Grade A

  • Type 2 diabetes mellitus

    FDA-approved (Mounjaro) — Grade A

  • Obstructive sleep apnea (with obesity)

    FDA-approved Dec 2024 — Grade B

  • Heart failure with preserved ejection fraction

    Phase 3 SUMMIT positive — Grade B

  • MASH / NASH

    Phase 2 SYNERGY-NASH positive — Grade B

  • Chronic kidney disease

    Phase 3 trials underway

§ The honest gaps

What we don’t
know yet.

Every peptide page on this site is required to include this section. Absence of evidence is information. If we don’t flag the gaps, we’re lying by omission.

  • !

    Long-term cardiovascular outcomes data is still maturing — SURPASS-CVOT will report in 2026.

  • !

    Whether the GIP component adds meaningful benefit beyond what extra weight loss alone explains is debated.

  • !

    Body composition during tirzepatide-induced weight loss — proportion of lean vs fat mass loss — is being actively studied.

  • !

    Optimal long-term dosing strategy after initial weight loss is achieved is not yet established.

  • !

    Comparative head-to-head with retatrutide and combination products will determine where it sits in five years.

§ On YouTube

What experts and
influencers say.

We index YouTube content discussing Tirzepatideand tag every speaker by credential and trust level. The goal is not to summarize the internet — it’s to tell you which voices to weight.

  • Tirzepatide vs Semaglutide: Comparing the Evidence

    Peter Attia MD·MD, Longevity / Internal Medicine

    Side-by-side analysis of SURPASS-2 and the practical implications for patients.

    Verified credentials

§ Citations

Every claim,
linked to source.

All 4 sources informing this page, with DOI or PubMed identifiers. Click through to the primary literature.

  1. [01]

    Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. · N Engl J Med · 2022

    RCTPMID 35658024
  2. [02]

    Tirzepatide vs semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)

    Frias JP, Davies MJ, Rosenstock J, et al. · N Engl J Med · 2021

    RCTPMID 34370970
  3. [03]

    Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA)

    Malhotra A, Grunstein RR, Fietze I, et al. · N Engl J Med · 2024

    RCTPMID 38912654
  4. [04]

    Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT)

    Packer M, Zile MR, Kramer CM, et al. · N Engl J Med · 2024

    RCTPMID 39555904

§ Adjacent peptides

Worth reading
alongside this.

Compare

Semaglutide

GLP-1 mono-agonist that tirzepatide outperformed in head-to-head SURPASS-2.

Read its grades

Compare

Retatrutide

Triple agonist (GIP/GLP-1/glucagon) — the next-gen step beyond tirzepatide.

Read its grades

Where to research further

Looking for Tirzepatide
for laboratory research?

Peptigrade does not sell peptides. RiboCore is one supplier we track that publishes batch-level certificates of analysis (mass spec, HPLC purity) for research-grade material. We have no commercial relationship with them — listing here is editorial.

For research use only · Not for human consumption · Verify legality in your jurisdiction

View at RiboCoreHow we evaluate suppliers →